Clinical trials: Pharmacogenomics
Hypertension
Pharmacogenomic Evaluation of Antihypertensive Responses 2
There are many medications available for the treatment of high blood pressure (hypertension), but finding the right one for a specific patient can be challenging.
- Trial name
- PEAR2 (NCT01203852)
- Testing
- Metoprolol, Chlorthalidone
- Where
- 3 sites in United States
- Volunteers
- 839 people
- Sponsor
- University of Florida
Atherothrombosis
Pharmacogenomics of Antiplatelet Response - II (PARes-II)
This clinical trial is examining the effect of 4-week aspirin therapy on platelet transcriptome in persons at high-risk for myocardial infarction or stroke due to family history of early-onset coronary artery disease.
- Trial name
- PARes-II (NCT01894555)
- Testing
- Aspirin
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Johns Hopkins University
Type 2 Diabetes
Pharmacogenomics of Thiazolidinediones
The purpose of this study is to determine predictors of response to pioglitazone, an anti-diabetic medication. The investigators know from randomized clinical trials that some 30% of patients do not respond to this type of…
- Trial name
- PPAR (NCT01135394)
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Rheumatoid Arthritis
Blood Sample Collection Study for Pharmacogenomic Characterization of Participants That Previously Received Namilumab in M1-1188-002-EM (PRIORA, [NCT01317797]) Study
The purpose of this study is to obtain blood samples from up to 14 participants who previously received namilumab in the previous study M1-1188-002-EM (PRIORA, [NCT01317797]) to correlate genetic markers with clinical outcomes.
- Trial name
- NCT02528786
- Testing
- No Intervention
- Volunteers
- 8 people
- Sponsor
- Takeda
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
This is a prospective phase II clinical study planned to be conducted at the Medical College of Wisconsin (MCW). After meeting the study criteria and enrollment, patients will be treated with a cladribine based salvage regimen…
- Trial name
- NCT03150004
- Testing
- Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen, Cladribine and Cytarabine (CLLDAC) Regimen
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Medical College of Wisconsin
Methamphetamine, Amphetamine Dependence
Study of Medical Treatment for Methamphetamine Addiction
Currently there are no medications approved for the treatment of methamphetamine addiction. Bupropion is an antidepressant that is approved by the Food and Drug Administration (FDA) for the treatment of depression and for…
- Conditions
- Methamphetamine, Amphetamine Dependence, Pharmacogenetics, Methamphetamine Dependence
- Trial name
- BUP PGx (NCT00833443)
- Testing
- Bupropion
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- University of California, Los Angeles
Adenocarcinoma, Neoplasms
Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors
This is an open label, two-part study of temsirolimus given as a 60-minute intravenous (IV) infusion once weekly to pediatric subjects with advanced solid tumors.
- Trial name
- NCT00106353
- Testing
- Torisel
- Where
- 30 sites in United States, Canada and 5 more
- Volunteers
- 71 people
- Sponsor
- Pfizer
Major Depressive Disorder (MDD)
Genomics Used to Improve DEpression Decisions
Evaluate the impact of GeneSight Psychotropic on response to psychotropic treatment as judged by the mean change in the 17-item Hamilton Depression (HAM-D17) score from baseline to end of Week 8 of the study.
- Trial name
- GUIDED (NCT02109939)
- Testing
- GeneSight Psychotropic
- Where
- 61 sites in United States
- Volunteers
- 1,398 people
- Sponsor
- Assurex Health Inc.
Healthy
Genetic Response to Warfarin in Healthy Subjects
The purpose of this study is to determine the importance of genetic differences on individuals' response to warfarin in a group of healthy subjects.
- Trial name
- NCT01520402
- Testing
- Warfarin
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Craniosynostosis
The Efficacy and Population Pharmacokinetics of Tranexamic Acid for Craniosynostosis Surgery
This research study is being performed to evaluate two different doses of Tranexamic acid (TXA) in children who have craniosynostosis and have been referred to Boston Children's Hospital for corrective surgery.
- Trial name
- NCT02188576
- Testing
- high dose TXA, Low dose TXA
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Boston Children's Hospital
HIV
Genetics and HIV-1 Protease Inhibitors
This study evaluated the blood levels of atazanavir according to a genetic makeup for CYP3A5 (cytochrome P450 3A5, an enzyme that metabolizes atazanavir).
- Trial name
- NCT01388543
- Testing
- Atazanavir
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Cancer, Depression
Pharmacogenomic Testing to Personalize Supportive Oncology
The purpose of this study is to evaluate pharmacogenomics (PGx) guided drug prescribing for pain and depression in patients with cancer.
- Conditions
- Cancer, Depression, Pain
- Trial name
- NCT04500301
- Testing
- Preemptive Pharmacogenomic Testing
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Wake Forest University Health Sciences
Ototoxicity
SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity
The primary objective of this study is to determine the safety and efficacy of SPI-1005 treatment in CF patients with active pulmonary exacerbation that are receiving an IV course of tobramycin, determined by comparing hearing…
- Trial name
- NCT02819856
- Testing
- SPI-1005 Ebselen 200mg Capsule x1, SPI-1005 Ebselen 200mg Capsule x2, SPI-1005 Ebselen 200mg Capsule x3
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Sound Pharmaceuticals, Incorporated
Depression, Anxiety
Retrospective Analysis of Outcomes With a Pharmacogenomic Algorithm
Antidepressants are among the most widely prescribed medications, yet only 35-45% of patients achieve remission following an initial antidepressant trial.
- Trial name
- UHS (NCT01632267)
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Assurex Health Inc.
Healthy Subjects
THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC
This will be an open-label, parallel group, multiple dose study in approximately 48 healthy male or female subjects of African American and Caucasian self-reported race, to assess the effect of CYP3A5 genotype on the PK of MVC…
- Trial name
- NCT02625207
- Testing
- Maraviroc (Part 1), Maraviroc (Part 2), Darunavir/cobicistat (Part 2)
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Evidence of Liver Transplantation, Rejection
Safety and Efficacy of Alemtuzumab in Pediatric Intestinal Transplantation
This open-label clinical trial will evaluate the safety and efficacy of Alemtuzumab (Campath, Bayer Corp., Pittsburgh) in children (0-17) and adults (18-25) receiving intestinal transplant.
- Conditions
- Evidence of Liver Transplantation, Rejection, ALEMTUZUMAB
- Trial name
- NCT01208337
- Testing
- Alemtuzumab
- Volunteers
- 23 people
- Sponsor
- University of Pittsburgh
Hepatocellular Carcinoma
Characterization of Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma (MK-0000-215)
The purpose of this study is to characterize the baseline variability of a panel of tissue (tumor and adjacent) and blood-based biomarkers obtained from participants with hepatocellular carcinoma (HCC).
- Trial name
- NCT01521780
- Testing
- MRI, Pathology, Blood Samples
- Volunteers
- 12 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
Pharmacogenomics of GLP1 Receptor Agonists
Healthy volunteers were recruited from the Old Order Amish population in Lancaster County, Pennsylvania. After providing informed consent, research participants were screened for eligibility.
- Trial name
- NCT05762744
- Testing
- Exenatide Injection (before the first FSIGT), Exenatide injection before the second FSIGT)
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Platelet Aggregation, Platelet Transcriptome
Pharmacogenomics of Antiplatelet Response - I
This clinical trial is examining the role of genetic polymorphism on the effect of clopidogrel (with or without aspirin) on platelet response in persons at high-risk for myocardial infarction or stroke due to family history of…
- Conditions
- Platelet Aggregation, Platelet Transcriptome, Coronary Artery Disease
- Trial name
- PARes-I (NCT01815008)
- Testing
- Clopidogrel, Aspirin
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Johns Hopkins University
Malignant Tumor of Ill-defined Site
LCI-NOS-PAIN-001: A Prospective, Pharmacogenomic-Driven Study of Pain Management in Oncology Outpatients
About half of all cancer patients seen in oncology clinics have pain at initial assessment; pain relief within a one-month period is seen in approximately one third of these patients and pain worsening in about one fifth.
- Trial name
- NCT02542397
- Testing
- Pharmacogenomic Testing
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Wake Forest University Health Sciences